|
DK1731511T3
(en)
|
1999-06-21 |
2015-10-26 |
Boehringer Ingelheim Pharma |
Bicyclic heterocyclic structures, pharmaceutical compositions containing these compounds, their use and process for their preparation
|
|
US7019012B2
(en)
|
2000-12-20 |
2006-03-28 |
Boehringer Ingelheim International Pharma Gmbh & Co. Kg |
Quinazoline derivatives and pharmaceutical compositions containing them
|
|
DE10204462A1
(de)
*
|
2002-02-05 |
2003-08-07 |
Boehringer Ingelheim Pharma |
Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
|
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
|
US20040044014A1
(en)
|
2002-04-19 |
2004-03-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
|
|
DE10221018A1
(de)
*
|
2002-05-11 |
2003-11-27 |
Boehringer Ingelheim Pharma |
Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
|
|
PE20040945A1
(es)
*
|
2003-02-05 |
2004-12-14 |
Warner Lambert Co |
Preparacion de quinazolinas substituidas
|
|
DE10307165A1
(de)
*
|
2003-02-20 |
2004-09-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
|
|
US7223749B2
(en)
|
2003-02-20 |
2007-05-29 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
|
US20050043233A1
(en)
*
|
2003-04-29 |
2005-02-24 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
|
|
DE10334226A1
(de)
*
|
2003-07-28 |
2005-02-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
|
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
|
SI1667991T1
(sl)
|
2003-09-16 |
2008-10-31 |
Astrazeneca Ab |
Kinazolinski derivati kot inhibitorji tirozin kinaze
|
|
US7456189B2
(en)
|
2003-09-30 |
2008-11-25 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
|
|
DE10349113A1
(de)
|
2003-10-17 |
2005-05-12 |
Boehringer Ingelheim Pharma |
Verfahren zur Herstellung von Aminocrotonylverbindungen
|
|
SI1746999T1
(sl)
*
|
2004-05-06 |
2012-01-31 |
Warner Lambert Co |
4-fenilamino-kinazolin-6-il-amidi
|
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
|
WO2006081741A1
(en)
*
|
2005-02-05 |
2006-08-10 |
Piaoyang Sun |
Quinazoline compounds or their medical salts and preparation and medical usage thereof
|
|
KR100832594B1
(ko)
*
|
2005-11-08 |
2008-05-27 |
한미약품 주식회사 |
다중저해제로서의 퀴나졸린 유도체 및 이의 제조방법
|
|
JP5688877B2
(ja)
|
2005-11-11 |
2015-03-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
癌疾患の治療用キナゾリン誘導体
|
|
EP2340837B1
(en)
*
|
2005-11-11 |
2017-03-15 |
Boehringer Ingelheim International GmbH |
Combination treatment of cancer comprising egfr/her2 inhibitors
|
|
DK1981863T3
(da)
*
|
2006-01-26 |
2013-01-02 |
Boehringer Ingelheim Int |
Fremgangsmåde til fremstilling af aminocrotonylaminosubtituerede quinazolinderivater
|
|
JP2010503717A
(ja)
|
2006-09-18 |
2010-02-04 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｅｇｆｒ変異を有する腫瘍を治療するための方法
|
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
|
EP2118075A1
(de)
|
2007-02-06 |
2009-11-18 |
Boehringer Ingelheim International GmbH |
Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
|
DK2245026T3
(da)
|
2008-02-07 |
2012-10-15 |
Boehringer Ingelheim Int |
Spirocycliske heterocycler, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåde til deres fremstilling
|
|
MY183041A
(en)
|
2008-05-13 |
2021-02-08 |
Astrazeneca Ab |
Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- {[1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
|
|
PE20100252A1
(es)
|
2008-06-06 |
2010-04-12 |
Boehringer Ingelheim Int |
Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
|
|
US8426430B2
(en)
|
2008-06-30 |
2013-04-23 |
Hutchison Medipharma Enterprises Limited |
Quinazoline derivatives
|
|
US8648191B2
(en)
|
2008-08-08 |
2014-02-11 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
|
WO2010054285A2
(en)
|
2008-11-10 |
2010-05-14 |
National Health Research Institutes |
Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
|
|
EP2387401A1
(en)
|
2009-01-14 |
2011-11-23 |
Boehringer Ingelheim International GmbH |
Method for treating colorectal cancer
|
|
EA021796B1
(ru)
|
2009-02-13 |
2015-09-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Способы улучшения гликемического контроля и снижения жира в организме, или профилактики увеличения жира в организме, или ускорения снижения жира в организме путем применения ингибитора sglt-2
|
|
EP2429527A1
(en)
*
|
2009-05-14 |
2012-03-21 |
Boehringer Ingelheim International GmbH |
New combination therapy in treatment of cancer and fibrotic diseases
|
|
EP2647375A1
(en)
|
2009-05-14 |
2013-10-09 |
Boehringer Ingelheim International Gmbh |
Combination of vargatef and dabigatran for the treatment of oncological and fibrotic diseases
|
|
DK2451445T3
(da)
|
2009-07-06 |
2019-06-24 |
Boehringer Ingelheim Int |
Fremgangsmåde til at tørre bibw2992, dets salte og faste farmaceutiske formuleringer omfattende denne aktive ingrediens
|
|
WO2011069962A1
(en)
|
2009-12-07 |
2011-06-16 |
Boehringer Ingelheim International Gmbh |
Bibw 2992 for use in the treatment of triple negative breast cancer
|
|
CN102686581B
(zh)
*
|
2009-12-21 |
2015-08-26 |
张强 |
喹唑啉衍生物
|
|
US20120107304A1
(en)
|
2010-04-27 |
2012-05-03 |
Boehringer Ingelheim International Gmbh |
Combination therapy in treatment of oncological and fibrotic diseases
|
|
SI2608792T1
(en)
|
2010-08-26 |
2018-02-28 |
Boehringer Ingelheim International Gmbh |
Methods of administering an egfr inhibitor
|
|
US9012464B2
(en)
|
2010-11-25 |
2015-04-21 |
Ratiopharm Gmbh |
Salts and polymorphic forms of Afatinib
|
|
CN103998040B
(zh)
|
2011-03-04 |
2017-03-29 |
江苏康缘药业股份有限公司 |
炔基取代的喹唑啉化合物及其使用方法
|
|
US8828391B2
(en)
|
2011-05-17 |
2014-09-09 |
Boehringer Ingelheim International Gmbh |
Method for EGFR directed combination treatment of non-small cell lung cancer
|
|
WO2012155339A1
(zh)
*
|
2011-05-17 |
2012-11-22 |
江苏康缘药业股份有限公司 |
4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
|
|
CN102838590B
(zh)
*
|
2011-06-21 |
2014-07-09 |
苏州迈泰生物技术有限公司 |
氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途
|
|
WO2013052157A1
(en)
|
2011-10-06 |
2013-04-11 |
Ratiopharm Gmbh |
Crystalline forms of afatinib di-maleate
|
|
CN103073539B
(zh)
*
|
2011-10-26 |
2016-05-11 |
齐鲁制药有限公司 |
4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
|
|
LT2805940T
(lt)
|
2012-01-17 |
2017-01-10 |
Astellas Pharma Inc. |
Pirazino karboksamido junginys
|
|
CN103772380A
(zh)
*
|
2012-10-23 |
2014-05-07 |
杨子娇 |
一类治疗房角狭窄的化合物及其用途
|
|
EP2951171A1
(en)
|
2013-02-01 |
2015-12-09 |
Boehringer Ingelheim International GmbH |
Radiolabeled quinazoline derivatives
|
|
US20140303097A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
CA2812519A1
(en)
|
2013-04-05 |
2014-10-05 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
HRP20190101T1
(hr)
|
2013-04-05 |
2019-03-08 |
Boehringer Ingelheim International Gmbh |
Terapeutske uporabe empagliflozina
|
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
CN113181161A
(zh)
|
2013-04-18 |
2021-07-30 |
勃林格殷格翰国际有限公司 |
药物组合物、治疗方法及其用途
|
|
CN103254182A
(zh)
*
|
2013-05-10 |
2013-08-21 |
苏州明锐医药科技有限公司 |
一种阿法替尼的制备方法
|
|
CN103254183B
(zh)
*
|
2013-05-10 |
2015-11-11 |
苏州明锐医药科技有限公司 |
阿法替尼的制备方法
|
|
WO2014180271A1
(zh)
*
|
2013-05-10 |
2014-11-13 |
苏州明锐医药科技有限公司 |
阿法替尼及其中间体的制备方法
|
|
CN103242303B
(zh)
*
|
2013-05-16 |
2015-03-25 |
苏州明锐医药科技有限公司 |
阿法替尼的制备方法
|
|
WO2014183560A1
(zh)
*
|
2013-05-16 |
2014-11-20 |
苏州明锐医药科技有限公司 |
阿法替尼及其中间体的制备方法
|
|
CN104513229A
(zh)
*
|
2013-09-28 |
2015-04-15 |
正大天晴药业集团股份有限公司 |
喹唑啉衍生物及其制备方法
|
|
CN103755688B
(zh)
*
|
2013-12-24 |
2015-11-18 |
江苏奥赛康药业股份有限公司 |
一种阿法替尼化合物的制备方法
|
|
US9242965B2
(en)
*
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
|
EP3089976B1
(en)
|
2014-01-02 |
2019-08-14 |
Teva Pharmaceuticals International GmbH |
Crystalline forms of afatinib dimaleate
|
|
CN105315263B
(zh)
*
|
2014-07-30 |
2018-11-27 |
正大天晴药业集团股份有限公司 |
阿法替尼中间体的合成方法
|
|
EP3023421A1
(en)
|
2014-11-21 |
2016-05-25 |
Sandoz Ag |
Crystalline forms of afatinib dimaleate
|
|
CN105801568B
(zh)
|
2015-01-15 |
2019-07-30 |
杭州普晒医药科技有限公司 |
阿法替尼一马来酸盐晶型及其制备方法和药物组合物
|
|
WO2016150340A1
(zh)
*
|
2015-03-20 |
2016-09-29 |
正大天晴药业集团股份有限公司 |
喹唑啉衍生物的盐及其制备方法
|
|
CN105175400B
(zh)
*
|
2015-09-29 |
2018-04-10 |
河北神威药业有限公司 |
一种阿法替尼中间体的制备方法
|
|
WO2017141271A1
(en)
*
|
2016-02-17 |
2017-08-24 |
Sun Pharmaceutical Industries Ltd. |
Stable pharmaceutical composition of afatinib
|
|
CN106442793B
(zh)
*
|
2016-10-21 |
2019-05-24 |
河北神威药业有限公司 |
一种制备阿法替尼的中间体及其对映异构体的检测方法
|
|
MA46742A
(fr)
|
2016-11-10 |
2019-09-18 |
Boehringer Ingelheim Int |
Composition pharmaceutique, méthodes de traitement et leurs utilisations
|
|
TWI808958B
(zh)
|
2017-01-25 |
2023-07-21 |
美商特普醫葯公司 |
涉及二芳基巨環化合物之組合療法
|
|
WO2019126136A2
(en)
*
|
2017-12-18 |
2019-06-27 |
Sterngreene, Inc. |
Pyrimidine compounds useful as tyrosine kinase inhibitors
|
|
CN110437163A
(zh)
*
|
2018-05-03 |
2019-11-12 |
斯特恩格林公司 |
作为酪氨酸激酶抑制剂的嘧啶类化合物
|
|
BR112021005513A2
(pt)
|
2018-09-25 |
2021-06-22 |
Black Diamond Therapeutics, Inc. |
derivados de quinazolina como inibidor de tirosina quinase, composições, métodos de fabricação e uso dos mesmos
|
|
CN109265449B
(zh)
*
|
2018-11-07 |
2021-11-23 |
沈阳工业大学 |
Egfr和her2双靶点酪氨酸激酶抑制剂及制备方法和用途
|
|
KR20210107069A
(ko)
|
2018-12-21 |
2021-08-31 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 컨쥬게이트와 키나아제 저해제의 조합
|
|
CN109824657A
(zh)
*
|
2019-03-26 |
2019-05-31 |
石药集团中奇制药技术（石家庄）有限公司 |
一种二马来酸阿法替尼新晶型及其制备方法和应用
|
|
EP4013749A1
(en)
|
2019-08-15 |
2022-06-22 |
Black Diamond Therapeutics, Inc. |
Alkynyl quinazoline compounds
|
|
CN110590682A
(zh)
*
|
2019-10-14 |
2019-12-20 |
重庆医科大学 |
一种制备阿法替尼杂质的方法以及制备的杂质
|
|
WO2021094379A1
(en)
|
2019-11-12 |
2021-05-20 |
Astrazeneca Ab |
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
|
|
JP2023510426A
(ja)
|
2020-01-20 |
2023-03-13 |
アストラゼネカ・アクチエボラーグ |
癌を治療するための上皮細胞増殖因子受容体チロシンキナーゼ阻害剤
|
|
US20210369709A1
(en)
|
2020-05-27 |
2021-12-02 |
Astrazeneca Ab |
EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
|
|
WO2023051687A1
(zh)
*
|
2021-09-30 |
2023-04-06 |
北京赛特明强医药科技有限公司 |
一种喹唑啉类化合物、组合物及其应用
|
|
KR20240168418A
(ko)
|
2022-03-31 |
2024-11-29 |
아스트라제네카 아베 |
암 치료를 위한 akt 억제제와 조합된 표피 성장 인자 수용체(egfr) 티로신 키나아제 억제제
|
|
WO2023209088A1
(en)
|
2022-04-28 |
2023-11-02 |
Astrazeneca Ab |
Bicyclic heteroaromatic compounds and their use in the treatment of cancer
|
|
WO2023209090A1
(en)
|
2022-04-28 |
2023-11-02 |
Astrazeneca Ab |
Bicyclic heteroaromatic compounds and their application in the treatment of cancer
|
|
WO2023209086A1
(en)
|
2022-04-28 |
2023-11-02 |
Astrazeneca Ab |
Bicyclic heteroaromatic compounds for treating cancer
|
|
AU2023262556A1
(en)
|
2022-04-28 |
2024-12-05 |
Astrazeneca Ab |
Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
|
|
JP2025525410A
(ja)
|
2022-06-27 |
2025-08-05 |
アストラゼネカ・アクチエボラーグ |
癌を治療するための上皮成長因子受容体チロシンキナーゼ阻害剤を伴う組み合わせ
|